Form 4: Cytek Biosciences CEO Reports Equity Vesting, Tax Withholding

Cytek Biosciences' President and CEO, Wenbin Jiang, reported the vesting of restricted stock units and employee stock options, alongside associated tax withholdings.

Summary

• Wenbin Jiang, President and CEO of Cytek Biosciences, Inc. (CTKB), reported multiple equity transactions on March 10, 2026.
• Transactions included the acquisition of common stock totaling 83,844 shares (15,708, 29,467, and 38,669 shares) through the vesting of Restricted Stock Units (RSU Awards).
• Concurrently, 20,988 shares (3,825, 7,747, and 9,416 shares) were disposed of at $4.23 per share to satisfy tax withholding obligations related to the RSU vesting.
• Jiang's direct beneficial ownership of common stock after these transactions is 5,422,683 shares.
• Additionally, Jiang was granted 485,545 employee stock options with an exercise price of $4.23, vesting over four years starting April 10, 2026, and expiring on March 9, 2036.
• New RSU Awards totaling 915,407 shares were also granted, vesting over four years with specific quarterly schedules starting May 18, 2026.
• Existing RSU Awards for 15,708, 29,467, and 38,669 shares also had vesting events on March 10, 2026, with their respective vesting schedules detailed.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral. It reports routine executive compensation activities (vesting and tax withholding) and new equity grants, which are standard for public companies and do not indicate a significant positive or negative shift in company fundamentals.

Positives

• The CEO's continued accumulation of equity through vesting and new grants aligns management's interests with long-term shareholder value.
• The grant of 485,545 employee stock options and 915,407 Restricted Stock Units indicates ongoing commitment to executive incentive programs.

Negatives

• The disposition of 20,988 shares to cover tax obligations, while routine, represents a reduction in direct share ownership.

Future Outlook

The detailed vesting schedules for the newly granted employee stock options and Restricted Stock Units indicate a long-term incentive structure for the CEO, aligning future performance with equity accumulation over the next four years.

Industry Context

StockSavvy.ai notes that routine Form 4 filings, such as this one detailing executive compensation and tax-related transactions, are common across the biotechnology and life sciences industry. These filings provide transparency into executive equity holdings and incentive structures, which are standard practices for publicly traded companies like Cytek Biosciences.

Related Party Transactions

• The transactions involve equity awards granted by Cytek Biosciences, Inc. to its President and CEO, Wenbin Jiang, which are considered related party transactions as part of executive compensation.

Stakeholder Impact

• Shareholders: The filing provides transparency into executive compensation and equity ownership, which can influence investor confidence. The alignment of executive incentives with long-term company performance through equity awards is generally viewed positively.
• Employees: The details of executive compensation may set a precedent or context for broader employee incentive programs.

Next Steps

• Continued vesting of 485,545 employee stock options over four years, with 1/48 vesting monthly starting April 10, 2026.
• Continued vesting of 915,407 RSU Award over four years, with specific quarterly vesting dates starting May 18, 2026.
• Continued vesting of existing RSU Awards (15,708, 29,467, 38,669 shares) according to their respective four-year quarterly schedules.

Key Dates

Keywords

Cytek Biosciences, CTKB, Wenbin Jiang, SEC Form 4, Insider Trading, Restricted Stock Units, RSU, Stock Options, Executive Compensation, Equity Vesting, Tax Withholding